Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Solara Active Pharma Sciences's EV-to-EBIT or its related term are showing as below:
NSE:SOLARAPP1'
s EV-to-EBIT Range Over the Past 10 Years
Min: -162.39 Med: 17.11 Max: 2687.79
Current: 46.77
During the past 10 years, the highest EV-to-EBIT of Solara Active Pharma Sciences was 2687.79. The lowest was -162.39. And the median was 17.11.
NSE:SOLARAPP1's EV-to-EBIT is ranked worse than 81.82% of 682
companies
in the Drug Manufacturers industry
Industry Median: 16.08
vs NSE:SOLARAPP1: 46.77
Solara Active Pharma Sciences (NSE:SOLARAPP1) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Solara Active Pharma Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was ₹12,948 Mil.
Solara Active Pharma Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹909 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solara Active Pharma Sciences EV-to-EBIT Related Terms
Solara Active Pharma Sciences EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solara Active Pharma Sciences EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Solara Active Pharma Sciences's EV-to-EBIT falls into.
Solara Active Pharma Sciences's current Enterprise Value is ₹34,058 Mil.
Solara Active Pharma Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹909 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a EV-to-EBIT of 37.48 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Solara Active Pharma Sciences and its competitors. This is 119% above median its historical median of 17.11. According to the industry distribution chart, Solara Active Pharma Sciences ranks #558 out of 682 companies in the Drug Manufacturers industry, placing it in the top 81.8%.
Is Solara Active Pharma Sciences' EV-to-EBIT too high?
Solara Active Pharma Sciences' current EV-to-EBIT of 37.48 is 119% above median its 10-year median of 17.11. The Drug Manufacturers industry median EV-to-EBIT is 16.08. Solara Active Pharma Sciences' value of 37.48 is 133.1% above this industry median. Based on the distribution chart, Solara Active Pharma Sciences ranks #558 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Solara Active Pharma Sciences has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Solara Active Pharma Sciences ranks #558 out of 682 companies for EV-to-EBIT. This places Solara Active Pharma Sciences in the lower half of its industry. The industry median EV-to-EBIT is 16.08. Solara Active Pharma Sciences' value of 37.48 is 133.1% above this benchmark. While the company's 10-year median is 17.11 vs. the industry median of 16.08, Solara Active Pharma Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solara Active Pharma Sciences's current EV-to-EBIT of 37.48 is 133.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Solara Active Pharma Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solara Active Pharma Sciences's current EV-to-EBIT is 37.48, which is 119% above median its own 10-year median of 17.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a current EV-to-EBIT of 37.48. The stock's GF Value™ is ₹208.54, compared to a current price of ₹267.45 — trading 28.2% above its estimated fair value. The current EV-to-EBIT is 37.48, which is 119% above median its 10-year median of 17.11 and 133.1% above the Drug Manufacturers industry median of 16.08. Solara Active Pharma Sciences' overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARAPP1), the current EV-to-EBIT is 37.48 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solara Active Pharma Sciences (NSE:SOLARAPP1) Overvalued in 2026?
Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be overvalued.
The current stock price of ₹267.45 is trading 28.2% above its estimated GF Value™ of ₹208.54.
Key valuation signals for NSE:SOLARAPP1:
EV-to-EBIT: 37.48 (119% above median its 10-year median of 17.11)
GF Value™: ₹208.54 vs. price of ₹267.45 (28.2% above fair value)
Industry Position: 133.1% above the Drug Manufacturers median (#558 of 682)
No single metric tells the full story. See the NSE:SOLARAPP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
64GF Score
Get the complete analysis for NSE:SOLARAPP1
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOLARAPP1 has been successfully added to your 
